QuantHealth Achieves Impressive 8x Financial Growth Across Life Sciences Engagements

The Company Has Established the Industry’s Most Advanced Portfolio of Clinical Trial Simulation Capabilities for Pharmaceutical and Biotechnology Companies

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, today announced a record year of growth, with sales increasing 8x through new and expanding engagements across life sciences organizations. This industry-leading pace of adoption, representing $5B in active R&D investments, reinforces the value of AI-driven clinical trial prediction to accelerate and simplify the costly, complex journey of bringing new drugs to market, while also identifying opportunities to improve the commercial impact of existing therapies.

Additionally, in 2025, QuantHealth established the industry’s most advanced clinical trial simulation portfolio – nearly doubling its clinical trial simulations to more than 600 trials – and achieving up to 90% accuracy across nearly 50 therapeutic areas, including oncology, respiratory, immunology, inflammation, and cardiometabolic diseases.

“This past year was pivotal for QuantHealth as we achieved unprecedented revenue growth, expanded our client base, and earned broader industry recognition for the results we deliver,” said Orr Inbar, CEO of QuantHealth. “This not only strengthens our position as a market leader in clinical trial simulations, but signals that we’ve built the momentum needed for success in 2026 and beyond,”

An estimated 90% of drugs fail in clinical trials, costing the pharmaceutical industry more than $50B annually, and delaying life-saving therapies for patients. As pharmaceutical companies seek to reduce risk, control development cost, and improve decision-making, they are increasingly harnessing predictive simulations to identify and prioritize promising drug candidates for research, understand the safety and efficacy of medicines earlier, and predict patients’ responses to treatment. With insights from QuantHealth’s AI-powered platform, which encompasses large-scale biological and clinical data, life sciences organizations are able to gain insights to improve the probability of clinical trials success and make smarter clinical research and commercial decisions.

“This year’s growth reflects the industry’s increasing need for enhanced decision-making across drug development, with a heightened focus on driving faster and more efficient clinical trials,” said Arnon Horev, Chief Operating Officer of QuantHealth. “Our growth is a result of our deep commitment to supporting our partners and strong execution across all of our clinical research and commercial engagements. We’re proud of the foundation we’ve built and are excited for the growth ahead.”

The company’s growth comes on the heels of QuantHealth’s recently announced strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment is accelerating the Company's efforts to bring scalable, patient-level simulations to the forefront of drug development.

To learn more about QuantHealth, please visit quanthealth.ai.

About QuantHealth

QuanthHealth is the global leader for AI clinical trial simulation, bringing together the industry’s most advanced clinical trial simulations portfolio — 600+ trial simulations across more than 45 diseases with up to 90% prediction accuracy — and the category’s largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for eight of the top 20 global pharmaceutical companies.

Mia Hinz
SolComms
QuantHealth@solcomms.co